SMA Newsroom

Have you ever wondered how the accessibility of your environment, your treatment status, or your sleep quality impact the way you are feeling? Why are some days easier than others? Why are some moments of the day or week more challenging? 

Biohaven announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for taldefgrobep alfa, a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy (SMA).